Assessing possibilities and preventing the risk of using disposables
Posted on March 13, 2019
Berthold Bodeker, Chief Scientist
Bayer Pharma AG
Introduction The demand scenario for many individual biopharmaceutical drugs such as monoclonal antibodies (MoAbs) is changing. With the implementation of personalised medicine resulting in drugs for specific, high responder subsets of patients, market volume per drug will decrease. In addition, in...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
